Romidepsin (FK228, Depsipeptide)

製品コードS3020 別名:FR 901228, NSC 630176

Romidepsin (FK228, Depsipeptide)化学構造

分子量(MW):540.7

Romidepsin (FK228, depsipeptide) is a potent HDAC1 and HDAC2 inhibitor with IC50 of 36 nM and 47 nM in cell-free assays, respectively.

サイズ 価格(税別)  
JPY 26062.00
JPY 79182.00
JPY 115702.00

カスタマーフィードバック(3)

  • An HIV-Gag-SLYNTVATL-specific CTL clone was labeled with Alexa-Fluor555 conjugated cholera toxin subunit B either cultured with 500 nM SAHA or 25 nM romidepsin for 20 hours, or maintained as an untreated control. These effector cells were combined with SLYNTVATL peptide pulsed target cells, matched on the restricting allele, in a collagen matrix medium containing sytox green viability dye. These mixtures were then plated in three separate wells of an 8-well cover slip and imaged by time-lapse brightfield and fluorescent microscopy. A. Shown are representative fields of view from the no treatment (upper panel), 500 nM SAHA (middle panel), and 25 nM romidepsin (lower panel) conditions advancing in time from left to right. Time stamps are given in hh[ratio]mm format. Clones described in the results are indicated with yellow arrows and killed target cells are indicated with white arrows in the upper right panel.

    PLoS Pathog 2014 10(8), e1004287. Romidepsin (FK228, Depsipeptide) purchased from Selleck.

    PLZF-RARa–nonexpressing and -expressing PLZFRARβ3 cells were treated with 5 nmol/L romidepsin for the indicated time points. Induction of the DNA DSB marker γH2AX was measured by Western blotting. β-Actin was used as a loading control.

    Mol Cancer Ther 2013 12(8), 1591-604. Romidepsin (FK228, Depsipeptide) purchased from Selleck.

  • Effects of combination of bort/romidepsin on HDAC6 inhibition and activation of ER stress signaling. HA cells were treated with combination of 15 nM bortezomib and 5 nM romidepsin or either drug alone for 24 hr. Expression of CHOP/GADD153 (green signals) and cleaved PARP (red signals) was detected by immunofluorescent staining. DAPI (blue signals) stained the cell nuclei.

    Int J Cancer 2014 135(12):2950-61. Romidepsin (FK228, Depsipeptide) purchased from Selleck.

製品安全説明書

HDAC阻害剤の選択性比較

生物活性

製品説明 Romidepsin (FK228, depsipeptide) is a potent HDAC1 and HDAC2 inhibitor with IC50 of 36 nM and 47 nM in cell-free assays, respectively.
特性 More effective than other classical HDAC inhibitors such as TSA, TPX, and butyrate.
ターゲット
HDAC1 [1]
(Cell-free assay)
HDAC2 [1]
(Cell-free assay)
36 nM 47 nM
体外試験

Unlike TSA, the active form redFK of Romidepsin strongly inhibits HDAC1 and HDAC2 with IC50 of 1.6 nM and 3.9 nM, respectively, but is relatively weak in inhibiting HDAC4 and HDAC6 with IC50 25 nM and 790 nM, respectively. Romidepsin is 17-23 times weaker than redFK in inhibiting these HDACs with IC50 of 36 nM, 47 nM, 510 nM, and 14 μM, respectively. Romidepsin treatment in HeLa cells induces histone acetylation and p21 expression with EC50 of 3.0 nM, more strongly than redFK with EC50 of 11 nM due to the instability of redFK. [1] In addition to G2/M arrest, Romidepsin treatment causes cyclin D1 downregulation and a p53-independent p21 induction, leading to inhibition of CDK and dephosphorylation of Rb resulting in growth arrest in the early G1 phase. [2] Romidepsin is 100 times more potent than TSA and 1,000,000 times more potent than butyrate in inhibiting the proliferation of the A549 cells. [3] Romidepsin inhibits the growth of U-937, K562, and CCRF-CEM cells with IC50 of 5.92 nM, 8.36 nM, and 6.95 nM, respectively. [5] Romidepsin promotes apoptosis in chronic lymphocytic leukemia (CLL) cells at a concentration corresponding to that at which H3 and H4 acetylation and HDAC inhibition occurs, selectively involving activation of caspase 8 and effector caspase 3, as well as down-regulation of c-FLIP protein. [6] In 11 of 13 (85%) renal cell carcinoma cell lines and in 16 of 37 (43%) other cancer cell lines, Romidepsin treatment up-regulates tumor death receptors, and potentiates natural killer (NK)-mediated tumor killing. [7] Romidepsin exhibits concentration-dependent cytotoxicity against a panel of mantle cell lymphoma (MCL) cell lines. [9]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SU-DHL4 NEDCW25E\WyuIG\pZYJqdGm2eTDBd5NigQ>? NF\XXJUzNjVvMUWgcm0> MoPrO|IhcA>? MoDJbY5lfWOnczDjfZRwfG:6aXPpeJkhcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZLDqA>? MnT0NlU4QTB7MEe=
U2932  MV3D[YxtKF[rYXLpcIl1gSCDc4PhfS=> M4nMUVIvPS1zNTDuUS=> M1HZbFczKGh? MVPpcoR2[2W|IHP5eI91d3irY3n0fUBqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7lduKh MUiyOVc6ODlyNx?=
OCI-LY7 NV;tRoVTS2WubDDWbYFjcWyrdImgRZN{[Xl? NEDVWHYzNjVvMUWgcm0> MnzJO|IhcA>? NFLRNmRqdmS3Y3XzJIN6fG:2b4jpZ4l1gSCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5mesLi M3\zT|I2PzlyOUC3
Farage MYrD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M2LuUlIvPS1zNTDuUS=> NGjiXnE4OiCq NWPNVnRzcW6mdXPld{BkgXSxdH;4bYNqfHliaX6gZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XMEoB?= MYGyOVc6ODlyNx?=
LY7/EBV M1XZV2NmdGxiVnnhZoltcXS7IFHzd4F6 MoTSNk42NTF3IH7N M3HXb|czKGh? Mm[5bY5lfWOnczDjfZRwfG:6aXPpeJkhcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZLDqA>? NIHZbIkzPTd7MEmwOy=>
U2932/EBV NEi2eYpE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NH\l[oMzNjVvMUWgcm0> MnfDO|IhcA>? NH7HdGdqdmS3Y3XzJIN6fG:2b4jpZ4l1gSCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5mesLi NXG2UYs6OjV5OUC5NFc>
HCT116 NUnGfG1KT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW[4OFBRPS13MECwJI5O NHX5b4kzPCCq MWLEUXNQ NUnYWWJocW6mdXPld{Bk\WyuIHTlZZRpKGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVz M2jSdlI2PDl{NUG1
ACH-2 NGrmN|hHfW6ldHnvckBCe3OjeR?= Mke1NU06KG6P MoqwNlQhcA>? MUPpcoR2[2W|IFjJWk0yKEWwdjDlfJBz\XO|aX;u NVja[3FVOjVzNEm0Olc>
MCF-10A MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPJR|UxRTBwMUhCtVAvODFibl2= MWOyOFk2PDh3Nh?=
MCF-7 NFzPWZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTFwMUFCtVAvOjBibl2= MWqyOFk2PDh3Nh?=
SK-BR-3 M1;qRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2HtWGlEPTB;MT6wNOKyOC5|NTDuUS=> Mk\uNlQ6PTR6NU[=
MDA-MB-231 M17Cd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4TORWlEPTB;MD62POKyOC5zNDDuUS=> M173e|I1QTV2OEW2
PC3 NEOyfWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\HTWM2OD1zLk[1xtExNjN3IH7N MVSyOFk2PDh3Nh?=
HCT116 M1zD[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTFwMEFCtVAvODBibl2= MX6yOFk2PDh3Nh?=
HCT116-p21-/- MmK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTFwMkdCtVAvOzdibl2= MWqyOFk2PDh3Nh?=
S1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXYTWM2OD15Lk[3xtExNjJ7IH7N MXyyOFk2PDh3Nh?=
SW620 NYrtbnU5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTBwOURCtVAvOjlibl2= MmrINlQ6PTR6NU[=
LOX-IMVI M2SzSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHyweGFKSzVyPUCuPFfDuTBwMEOgcm0> Mm\sNlQ6PTR6NU[=
UACC-62 NIT6[IFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVy2OmxvUUN3ME2wMlU3yrFyLkG2JI5O MmO2NlQ6PTR6NU[=
MDA-MB-435 M3fFTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHiTWM2OD1yLkmwxtExNjB4IH7N NHvMNYgzPDl3NEi1Oi=>
SF-295 NFXQXnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\wPWpKSzVyPUCuPFjDuTBwMUWgcm0> NFLocGszPDl3NEi1Oi=>
A549 M33Jc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2TFTGlEPTB;MT6yOuKyOC5{NDDuUS=> NF;iV40zPDl3NEi1Oi=>
H460 MmnTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTJwNUlCtVAvQDBibl2= NIjyN2wzPDl3NEi1Oi=>
EKVX M4nPOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYi1OFRGUUN3ME2xMlM{yrFyLkO0JI5O NVTNSml7OjR7NUS4OVY>
H146 MkjjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLETWM2OD1yLkKyxtExNjB5IH7N MVWyOFk2PDh3Nh?=
H526 NEHUOWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{DXN2lEPTB;MD6xOeKyOC5yMzDuUS=> M1XyWlI1QTV2OEW2
HuT-78 NUXSXJI3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUfjTpJYUUN3ME2xMlc{yrFyLkS0JI5O M2jpU|I1QTV2OEW2
HA M1vycmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MorlNE43OjVvMUDuUS=> NEDZTo01QCCq MljSbY5lfWOnczDhJJNq\26rZnnjZY51dHlic4Tyc45o\XJiaX7obYJqfGmxbjDv[kBk\WyuIIDyc4xq\mW{YYTpc44h[29vdILlZZRm\CC5aYToJIJwenSnen;tbYI> NHLmXFIzPDd5MUWxNC=>
MS-275 MmnVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlPYNE43OjVvMUDuUS=> Ml\KOFghcA>? NWfr[FhncW6mdXPld{BiKHOrZ37p[olk[W62bImgd5Rzd26pZYKgbY5pcWKrdHnvckBw\iClZXzsJJBzd2yrZnXyZZRqd25iY3:teJJm[XSnZDD3bZRpKGKxcoTlfo9ucWJ? Mn3kNlQ4PzF3MUC=
CD4 T MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWLNcJh5PDhiaB?= MnO5SWM2OD12LkZCtVEvOCCwTR?= NWj2OmdzOjR5MkK0OVQ>
CD4 T M{Hxfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUH4O3A6PDhiaB?= NI\xdVVESzVyPUGwO:KyOTJ4IH7N Ml;5NlQ4OjJ2NUS=
CD4+ T M1L2T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvFR|UxRTNibl2= MoHLNlQ1QTVzMEW=
A549 NGCyR|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\BU|QyOOLCk{GwNOKhdk1? NIHLfVUzPC9|Nj:0PEBp Mn\abY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEBkd26lZX70doF1cW:wLTDhcoQhfGmvZT3k[ZBmdmSnboSgcYFvdmW{ M2HXWlI1PDh3N{m5
JJN3 Ml;xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M36wfFI1NzR6IHi= NULTbJRYTUN3MEyx5qCKdk19IES45qCKcA>? MUiyOFA{ODF3MB?=
OPM-2 M2XKVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGmyNW4zPC92ODDo M4rBV2VEPTC|PUJihKlvVTtiNElihKlp MUeyOFA{ODF3MB?=
RPMI-8226 MmfjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHzlWHYzPC92ODDo MmKwSWM2OHN;MT645qCKdk19IES45qCKcA>? M3;MbFI1ODNyMUWw
U266 NWS3b4JrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVXROmtQOjRxNEigbC=> MmOxSWM2OHN;MUFihKlvVTtiNElihKlp M1;tWFI1ODNyMUWw
CA46 NUnhfHd3SXCxcITvd4l{KEG|c3H5 M2jOcVYhcA>? NX;obpVNcW6mdXPld{BjdHWwdDDhdI9xfG:|aYO= NWX4XGdpOjN7Nk[xOlQ>
DG75 MXjBdI9xfG:|aYOgRZN{[Xl? NUH5WI04PiCq NVfZfI5GcW6mdXPld{BvdyCjcH;weI9{cXN? NF76W28zOzl4NkG2OC=>
Ramos MVHBdI9xfG:|aYOgRZN{[Xl? NHLxVXE3KGh? NEOxOo5qdmS3Y3XzJIV5fGWwc3n2[UBieG:ydH;zbZM> M3rKNFI{QTZ4MU[0
ST486 NIjiN5RCeG:ydH;zbZMhSXO|YYm= M2j6TFYhcA>? M2XNTIlv\HWlZYOg[Zh1\W6|aY\lJIFxd3C2b4Ppdy=> NECxZWUzOzl4NkG2OC=>
HuT78 MXjBdI9xfG:|aYOgRZN{[Xl? NUnPdm9lOS9zMD:xNFAhdk1? MmXnOFghcA>? M33YdIlv\HWlZYOgZZBweHSxc3nzJIF1KDFibl2= NXnpfGFCOjN3M{K3N|I>
DpVp35 NIq2XWdCeG:ydH;zbZMhSXO|YYm= M{HhRVEwOTBxMUCwJI5O NGW5eVg1QCCq MYDpcoR2[2W|IHLseY51KGGyb4D0c5Nqew>? NHjrUIozOzV|MkezNi=>
DpVp50 MVPBdI9xfG:|aYOgRZN{[Xl? MVuxM|ExNzFyMDDuUS=> NGHLfmY1QCCq NXH6clN[cW6mdXPld{BjdHWwdDDhdI9xfG:|aYO= MlT0NlM2OzJ5M{K=
DpP75  Mo\kRZBweHSxc3nzJGF{e2G7 MUexM|ExNzFyMDDuUS=> MVS0PEBp MXfpcoR2[2W|IHLseY51KGGyb4D0c5Nqew>? MWSyN|U{Ojd|Mh?=
SKOV-3 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVmx5qCUOjCwTR?= Ml\4O|IhcA>? MUjEUXNQ NGHwV5Zz\WS3Y3XzJINmdGxidnnhZoltcXS7IHHsc45mKGGwZDDjc41jcW6nZDD3bZRpKGOrc4DsZZRqdg>? NXWzSFh{OjNyMUCzOFg>
Brca1 WT M2n3U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnnLNgKBmzJybl2= MYW3NkBp MmPrSG1UVw>? NVLQXXN1emWmdXPld{Bk\WyuII\pZYJqdGm2eTDhcI9v\SCjbnSgZ49u[mmwZXSge4l1cCClaYPwcIF1cW5? Mn24NlMxOTB|NEi=
Brca1 Null MoiwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrmNgKBmzJybl2= M1K4fFczKGh? M4\4UGROW09? NVXDV5RkemWmdXPld{Bk\WyuII\pZYJqdGm2eTDhcI9v\SCjbnSgZ49u[mmwZXSge4l1cCClaYPwcIF1cW5? MWiyN|AyODN2OB?=
OVCAR-8  M1jlNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4C2OlHjiJN{MH7N MW[3NkBp Mm[xSG1UVw>? MojydoVlfWOnczDj[YxtKH[rYXLpcIl1gSCjbH;u[UBidmRiY3;tZolv\WRid3n0bEBkcXOybHH0bY4> MY[yN|AyODN2OB?=
NCI/ADR-RES MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\hRYxJOeLCk{Kwcm0> NVy4fY5YPzJiaB?= NH[0PFBFVVOR NVm3bXd4emWmdXPld{Bk\WyuII\pZYJqdGm2eTDhcI9v\SCjbnSgZ49u[mmwZXSge4l1cCClaYPwcIF1cW5? NV7EdFNsOjNyMUCzOFg>
HCT116 NEjtWWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXVNlE2KG6PLUWwJO69VQ>? MWCyOEBp MYnEUXNQ NI\jeI1qdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5meg>? NYLCN45HOjJ7MkS5OVg>
RKO M3qzXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXzhXIFnPSCwTT21NEDPxE1? NFL2flMzPCCq MXrEUXNQ NVywfHlUcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XJ? M2\lSlIzQTJ2OUW4
CO115 NWmyPVVjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXu1JI5ONTVyIN88US=> M3\XPFI1KGh? M3X3O2ROW09? M2LUcIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVz NITCWnUzOjl{NEm1PC=>
HFS MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPKOUBvVQ>? M4rFclI1NzR6L{eyJIg> NF7KcnFqdmirYnn0d{Bk\WyuIHfyc5d1cCC2aX3lMYRmeGWwZHXueIx6 NUC2bJZROjJzME[yPFI>
LNCaP MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{nRfFUhdk1? M{X0PFI1NzR6L{eyJIg> NYjCd5lHcW6qaXLpeJMh[2WubDDndo94fGhidHnt[U1l\XCnbnTlcpRtgQ>? Ml\ENlIyODZ{OEK=
A549 MlLZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPrSIx2PSCwTR?= NHnNTogzPC92OD:3NkBp M{npU4lvcGmkaYTzJINmdGxiZ4Lve5RpKHSrbXWt[IVx\W6mZX70cJk> MVOyNlExPjJ6Mh?=
697  M1qxbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzQfVRKSzVy4pEJQgKBkTJwNdMgcm0> NGHDRoYzOTV|OEKxOi=>
697-R M3XkcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|Ux6oDLPfMAjVgvPsLibl5CpC=> NUDST4p3OjF3M{iyNVY>
HUT78 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rJWWlEPTB;MTDuUS=> Mli0NlEyQTh3NEW=
THJ-16T NFrUT3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDCPVgyKG6P NX:wb3RmOjRiaB?= MnvobY5pcWKrdIOgZ4VtdCCpcn;3eIg> MoTsNlA5OTB3Nki=
HCT116 MXXGeY5kfGmxbjDBd5NigQ>? NVTn[5lNOjBibl2= NFP5TIs5KGh? MmnMcY9lfWyjdHXzJJRz[W6|Y4LpdJQhdGW4ZXzzJIZweiCqdX7kdoVleyCxZjDn[Y5meyCrbjDlbZRp\XJiZHny[YN1cW:w MWmyNFc{QTR3NB?=
B104  NXTDbYxUTnWwY4Tpc44hSXO|YYm= NHToOowzKG6P MXuyOE81QC95MjDo MnzkbY5kemWjc3XzJJRp\SC|dYLmZYNmKGW6cILld5Nqd25ib3[gR2QzOMLi NFfJVpAzODZ6NkWwOS=>
HL-60  NUS0[WxbS3m2b4TvfIlkcXS7IFHzd4F6 M2XiV|EuPTByIH7N MY[yOEBp MnzYbY5lfWOnczDjfZRwfG:6aXPpeJkhcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZLDqA>? NH\kb3AzODZ{NEG2Ny=>
HP100 NILRW5BEgXSxdH;4bYNqfHliQYPzZZk> NHzpXm0yNTVyMDDuUS=> MlfvNlQhcA>? MXHpcoR2[2W|IHP5eI91d3irY3n0fUBqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7lduKh NFX4WWMzODZ{NEG2Ny=>
HL-60  MoXsSpVv[3Srb36gRZN{[Xl? NXy5eWRIOTBibl2= M3u0O|QwPi9zNjDo Ml3CbY5lfWOnczD0bIUh\2WwZYLheIlwdiCxZjDofYRzd2enbjDw[ZJwgGmmZTDmdo9uKDSq NFPzZYQzODZ{NEG2Ny=>
HP100 M2KyTGZ2dmO2aX;uJGF{e2G7 MXWxNEBvVQ>? M4\xSFQwPi9zNjDo NXzuNndEcW6mdXPld{B1cGViZ3Xu[ZJifGmxbjDv[kBpgWS{b3flckBx\XKxeHnk[UBnem:vIETo MYiyNFYzPDF4Mx?=
HL-60  NWjrNpduTnWwY4Tpc44hSXO|YYm= NX\v[I1VOTBvNUCwJI5O M4PMdlQhcA>? NWLaRoRs\GWlcnXhd4V{KHSqZTDobZN1d26nIHTlZYNmfHmuYYPlJEhJTEGFKTDhZ5Rqfmm2edMg M3vEeVIxPjJ2MU[z
HP100 NUfOVY1vTnWwY4Tpc44hSXO|YYm= MojMNVAuPTByIH7N MWm0JIg> M4jvc4Rm[3KnYYPld{B1cGViaHnzeI9v\SCmZXHj[ZR6dGG|ZTCoTGRCSyliYXP0bZZqfHoEoB?= Mlq5NlA3OjRzNkO=
11z Mn:xT4lv[XOnIFHzd4F6 M3zoVFMuOTByIH7N M1viR5Jm\HWlZYOgTGRCSyCnbor5cYF1cWNiYXP0bZZqfHliKFnDOVDDqD1iNj61JOKyKDBwNjDucY9tN0xr NXPkOZp2OjB4MEWxOFQ>
SKOV-3 M1fQ[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH7S[m81NzhxMU[gcm0> MUm0PEBp NIfRTZRqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5meg>? M3n4SFIxPDB2NU[0
OVCAR-3 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVH2PW1LPC96L{G2JI5O NEnX[I81QCCq NV\OO4ZPcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XJ? MVWyNFQxPDV4NB?=
HBL-2 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLKVoFYOi1zMDDuUS=> NIq1bWYzPCCq M4PDeWlEPTB;ND6zJI5O M132XVIxODZ6MEiw
Jeko-1 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWrZOZNyOi13MDDuUS=> M{DBb|I1KGh? MmqxTWM2OD1zMTDuUS=> M4\NUlIxODZ6MEiw
Granta-519 M2TyTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVW1MVQxKG6P M2nrO|I1KGh? Ml3ETWM2OD13OD61JI5O MkPMNlAxPjhyOEC=
L1236 M3;FZWN6fG:2b4jpZ4l1gSCDc4PhfS=> MXGxJI5ONTFyMDFOwG0> NIOxfII1QCCq M33pc2VEPTB;MD6wO{DPxE1? Mli0NVkzOzN2N{C=
L428 MULDfZRwfG:6aXPpeJkhSXO|YYm= MlrGNUBvVS1zMECg{txO MYq0PEBp NF;MXYFGSzVyPUCuOFMh|ryP MlnFNVkzOzN2N{C=
KM-H2 M3PIUmN6fG:2b4jpZ4l1gSCDc4PhfS=> MlvMNUBvVS1zMECg{txO NELUXZA1QCCq M{PGTGVEPTB;MD61PEDPxE1? M13UU|E6OjN|NEew
L540Cy MojZR5l1d3SxeHnjbZR6KEG|c3H5 MnLmNUBvVS1zMECg{txO NVj4Vmg2PDhiaB?= MYHFR|UxRTBwMU[g{txO NE\vTmcyQTJ|M{S3NC=>
G401 M{iwRmZ2dmO2aX;uJGF{e2G7 NH3GbmUyOCCwTR?= MWiyOE81QC95MjDo MXHEUXNQ NIXzbVdqdmO{ZXHz[ZMhS0SNTkHDJIV5eHKnc4Ppc44> MX[xPVIzOTV6Nh?=
STM91-01 M1\LTGZ2dmO2aX;uJGF{e2G7 NUHneGp2OTBibl2= NEHmOpkzPC92OD:3NkBp M4r4WmROW09? M1v1T4lv[3KnYYPld{BETEuQMVOg[ZhxemW|c3nvci=> MXixPVIzOTV6Nh?=
SJSC  MX7GeY5kfGmxbjDBd5NigQ>? MVOxNEBvVQ>? MXmyOE81QC95MjDo NYr4fmNKTE2VTx?= MnLibY5kemWjc3XzJGNFU05zQzDlfJBz\XO|aX;u MmmxNVkzOjF3OE[=
BT16  MWjGeY5kfGmxbjDBd5NigQ>? MVexNEBvVQ>? M3rlb|I1NzR6L{eyJIg> NV3SeVRZTE2VTx?= MXrpcoNz\WG|ZYOgR2RMVjGFIHX4dJJme3Orb36= MY[xPVIzOTV6Nh?=
NCI-H1299 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXrGdpNCUUN3ME20MlbDuTBwMjDu[{9udA>? NIjsblUyQTF5OUi5NC=>
NCI-2882 NFvkc4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTFwNtMxNE4xPCCwZz;tcC=> M1HlNVE6OTd7OEmw
HCC95 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH33WVlKSzVyPUKuOeKyOC5yNTDu[{9udA>? MXmxPVE4QTh7MB?=
NCI-H23 NY\oS4h1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoH4TWM2OD1{LkpCtVAvOiCwZz;tcC=> NI\NO2EyQTF5OUi5NC=>
NCI-H157 MljOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUn6bIFSUUN3ME2xMlbDuTBwMEKgcocwdWx? NVrLe5I2OTlzN{m4PVA>
NCI-H460 NIPERmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTJwMdMxNE4xPyCwZz;tcC=> MonCNVkyPzl6OUC=
NCI-H1975 Mn\uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTFwM9MxNE4xPCCwZz;tcC=> M1HWclE6OTd7OEmw
NCI-H820 M1HBdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;QTWM2OD1{LkVCtVAvOSCwZz;tcC=> NXnTe2JZOTlzN{m4PVA>
NCI-H1650 NEOyUm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HS[GlEPTB;ND65xtExNjNibnevcYw> M2\q[lE6OTd7OEmw
DTC1 M1rOXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTBwNUGgcm0> NFTlR40yQDV4NkK0Oi=>
KAO NV22[5ZzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vMXmlEPTB;MD65NUBvVQ>? NVrDcWJWOTh3Nk[yOFY>
SU-CCS-1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm[4TWM2OD1yLki5JI5O NHjYbmUyQDV4NkK0Oi=>
SYO-1 NEHGU2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEDLSVJKSzVyPUCuOlchdk1? Mkf5NVg2PjZ{NE[=
FUJI M{PQNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLRTWM2OD1zLkOxJI5O MUmxPFU3PjJ2Nh?=
SKNMC MoDIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{izZmlEPTB;MT6xO{BvVQ>? MVmxPFU3PjJ2Nh?=
402-91 MorhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoTKTWM2OD1zLkK2JI5O MXKxPFU3PjJ2Nh?=
1765-92 NG\zd45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1TxV2lEPTB;MT63O{BvVQ>? M3m4R|E5PTZ4MkS2
JN-DSRCT-1 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3O2R2lEPTB;MT6yOUBvVQ>? MkT3NVg2PjZ{NE[=
NMS-2PC MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;MUYZrUUN3ME2wMlgyKG6P MVixPFU3PjJ2Nh?=
HL60 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\YUXlKSzVyPUGuPFYhdk1? M3m5[FE5PTZ4MkS2
A549 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{DaR2lEPTB;Mz6yOEBvVQ>? MkfHNVg2PjZ{NE[=
SW480 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGG1NpdKSzVyPUKuOlkhdk1? MnnONVg2PjZ{NE[=
MCF7 NIO1NpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1rKN2lEPTB;Mz61OUBvVQ>? MVexPFU3PjJ2Nh?=
PC-3 NUPRNIpoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnrsTWM2OD1{LkWxJI5O NHvLRZoyQDV4NkK0Oi=>
MMRU MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnn3TWM2OD1{LkW3JI5O MlTSNVg2PjZ{NE[=
Hs68 MmTRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUjNc29GUUN3ME2+NVAhdk1? NYi2dXczOTh3Nk[yOFY>
hMSC-001F MkLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH7WTpZKSzVyPU6xNEBvVQ>? NYjqZpVLOTh3Nk[yOFY>

多くの細胞株試験データを見る場合、クリックしてください

体内試験 Romidepsin treatment potently inhibits the neovascularization of chick embryo and that of adult mice in the Matrigel plug assay. [4]Administration of Romidepsin at 0.1-1 mg/kg twice a week significantly prolongs the survival of mice bearing U-937 lymphoma, with median survival times of 30.5 (0.56 mg/kg) and 33 days (0.32 mg/kg), respectively (vs. 20 days in control mice). [5]

お薦めの試験操作(参考用のみ)

キナーゼ試験:

[1]

+ 展開

HDAC-inhibitory activity:

For the enzyme assay, 10 μL of [3H]acetyl-labeled histones (25,000 cpm/10 μg) are added to 90 μL of the HDAC enzyme fraction extracted from 293T cells overexpressing HDAC1 or HDAC2 in the presence of increasing concentrations of Romidepsin, and the mixture is incubated at 37 °C for 15 minutes. The enzyme reaction is linear for at least 1 hour. The reaction is stopped by the addition of 10 μL of concentrated HCl. The released [3H]acetic acid is extracted with 1 mL of ethylacetate, and 0.9 mL of the solvent layer is taken into 5 mL of aqueous counting scintillant II solution for determination of radioactivity. The IC50 values are determined from at least three independent dose-response curves.
細胞試験:

[3]

+ 展開
  • 細胞株: HL60, Jurkat, A549, and MCF-7
  • 濃度: Dissolved in DMSO, final concentrations ~10 μM
  • 反応時間: 72 hours
  • 実験の流れ:

    Cells are exposed to various concentrations of Romidepsin for 72 hours in 96-well plates. 20 μL of 5 mg/mL MTT solution in PBS is added to each well for 4 hours. After removal of the medium, 170 μL of DMSO is added to each well to dissolve the formazan crystals. The absorbance at 540 nm is determined. In addition, cells are incubated with trypan blue, and the numbers of blue (dead) cells and transparent (live) cells are counted in a hemocytometer. For cell cycle analysis, cells are incubated for 30 minutes in propidium iodide staining solution containing 0.05 mg/mL propidium iodide, 1 mM EDTA, 0.1% Triton X-100, and 1 mg/mL RNase A in PBS. The suspension is then passed through a nylon mesh filter and analyzed on a Becton Dickinson FACScan.


    (参考用のみ)
動物試験:

[5]

+ 展開
  • 動物モデル: Male scid mice inoculated i.p. with U-937 cells
  • 製剤: Dissolved in DMSO, and diluted in saline
  • 投薬量: ~1 mg/kg once or twice a week
  • 投与方法: Treated i.p.
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 10 mg/mL (18.49 mM)
Water Insoluble
Ethanol Insoluble
体内 左から右までの手順で、溶剤を製品に加えることです:
2% DMSO+30% PEG 300+5%Tween 80+ddH2O
いい結果が出るために、混じった後、直ちに使うと推めます。
5mg/mL

* 溶解度検測はSelleck技術部門によって行いますので、文献より提供された溶解度と差異がある可能性がありますが、生産工芸と不同ロット(lot)で起きる正常な現象ですから、ご安心ください。

化学情報

分子量 540.7
化学式

C24H36N4O6S2

CAS No. 128517-07-7
保管
別名 FR 901228, NSC 630176

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00048334 Completed Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) October 26, 2002 Phase 1
NCT00094978 Terminated Carcinoma, Small Cell|Carcinoma, Non-Small-Cell Lung|Esophageal Neoplasms|Mesothelioma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) October 25, 2004 Phase 1
NCT01445340 Terminated Mycosis Fungoides|Cutaneous T-Cell Lymphoma|Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) April 21, 2007 Phase 1
NCT02616965 Not yet recruiting Cutaneous T-cell Lymphoma (CTCL) Fox Chase Cancer Center|Seattle Genetics, Inc.|Celgene Corporation April 2017 Phase 1
NCT02850016 Recruiting Human Immunodeficiency Virus (HIV) Rockefeller University|University Hospital of Cologne|Aarhus University Hospital December 2016 Phase 2
NCT02757248 Withdrawn PTCL|CTCL Anne Beaven, MD|National Comprehensive Cancer Network|Boehringer Ingelheim|Duke University November 2016 Phase 1

技術サポート

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

Handling Instructions

他の質問がある場合は、お気軽くお問合せください。

  • * 必須

HDACシグナル伝達経路

HDAC Inhibitors with Unique Features

相関HDAC製品

Tags: Romidepsin (FK228, Depsipeptide)を買う | Romidepsin (FK228, Depsipeptide) ic50 | Romidepsin (FK228, Depsipeptide)供給者 | Romidepsin (FK228, Depsipeptide)を購入する | Romidepsin (FK228, Depsipeptide)費用 | Romidepsin (FK228, Depsipeptide)生産者 | オーダーRomidepsin (FK228, Depsipeptide) | Romidepsin (FK228, Depsipeptide)化学構造 | Romidepsin (FK228, Depsipeptide)分子量 | Romidepsin (FK228, Depsipeptide)代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID